• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: EDWARDS LIFESCIENCES EDWARDS SAPIEN XT TRANSCATHETER HEART VALVE; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

EDWARDS LIFESCIENCES EDWARDS SAPIEN XT TRANSCATHETER HEART VALVE; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED Back to Search Results
Model Number 9300TFX23A
Device Problems Malposition of Device (2616); Device-Device Incompatibility (2919)
Patient Problem Not Applicable (3189)
Event Date 10/14/2015
Event Type  Injury  
Manufacturer Narrative
(b)(4).At this time, the thv is not indicated for use inside a native mitral valve, and there is no guidance in the thv training manual on usage of a sapien xt valve within a mitral valve.Testing performed by edwards documents the phenomena of high placement of the thv in a native aortic annulus, which would be relevant in the scenario of a thv in a mitral valve, as well.Inaccurate deployment (too high or too low in the mitral valve) could result in clinically significant hemodynamic compromise, implantation of a second valve, embolization of the valve, and/or may require additional intervention to secure or remove the valve.In this case, the exact cause of the malposition of the initial valve cannot be confirmed.It is possible that procedural factors (miscommunication during the initial valve positioning and deployment) may have contributed to this event.
 
Event Description
During a trans-septal valve-in-valve (sapien xt in an existing bioprosthetic mitral ring) procedure, a 23mm sapien xt was placed too atrial, approximately 90:10 atrial/ventricular.Due to concerns about possible valve migration, a second sapien xt valve was deployed to anchor the initial valve.Minimal paravalvular leak (pvl) was observed post valve deployment.The procedure was completed and the patient was transferred in stable condition.At the time of this report, the patient was doing well.It was speculated that possible miscommunication during the initial valve positioning and deployment contributed to this event.No device issues were reported.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EDWARDS SAPIEN XT TRANSCATHETER HEART VALVE
Type of Device
AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED
Manufacturer (Section D)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer (Section G)
EDWARDS LIFESCIENCES LLC
1 edwards way
irvine CA 92614
Manufacturer Contact
frances preston
1 edwards way
irvine, CA 92614
9492505190
MDR Report Key5196066
MDR Text Key30203321
Report Number2015691-2015-02932
Device Sequence Number1
Product Code NPT
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P130009
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,health
Reporter Occupation Physician
Remedial Action Other
Type of Report Initial
Report Date 10/14/2015
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/02/2015
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date12/16/2016
Device Model Number9300TFX23A
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received10/14/2015
Date Device Manufactured01/15/2015
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age82 YR
-
-